TCTR20240718005尚未招募2 期
A Multicenter, Single-arm, Open-label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Cefiderocol in Hospitalized Pediatric Patients from Birth to less than 3 Months of Age with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- N/A (No limit) 至 3 Months（—）
- 性别
- All
入选标准
- •1. Written informed consent has been provided by parent(s) or legally authorized representative(s) in accordance with local regulatory requirements
- •2. Hospitalized infants from birth to less than 3 months (less than 90 days) of age at the time written informed consent is provided. Enrollment of premature infants will not be restricted, but they must have a GA equal or greater than 26 weeks, PNA of 0 to 3 months, and weight of at least 1 kilogram (kg)
- •3. Require systemic IV antibiotic treatment for suspected or confirmed aerobic Gram-negative infections including, but not limited to, complicated urinary tract infection, complicated intra-abdominal infection, hospital-acquired/ ventilator-associated bacterial pneumonia, and BSI/sepsis
- •4. For the multiple-dose phase, within 72 hours of the start of potentially effective treatment with SOC antibiotics for the suspected or confirmed primary aerobic Gram-negative infection
排除标准
- •1. Documented history of any moderate or severe hypersensitivity or allergic reaction to any beta-lactam antibiotic
- •2. Life expectancy of less than 72 hours after enrollment
- •3. Urine output less than 1.0 milliliter/kg/hour within the 24 hours prior to study drug administration on Day 1
- •4. Serum creatinine value greater than the maximum for GA and PNA shown below within the 24 hours prior to study drug administration on Day 1
- •5. Neonatal acute kidney injury, defined as a serum creatinine level greater than 1.5 milligrams per decilieter (133 micromoles/ liter) or an increase of 0.3 mg per dL (17 to 27 micromol/L per day) from a previous lower value
- •6. Acute kidney injury based on an increase in serum creatinine equal or more than 0.3 mg/dL within 48 hours from an established baseline value
- •7. Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
- •8. Receiving renal replacement therapy
- •9. Received any other investigational medicinal product within 30 days of study drug administration
- •10. Receiving treatment with a vasopressor at Screening
- •11. Has a confirmed or strongly suspected infection at Screening with a pathogen known to be resistant to cefiderocol or only a Gram-positive pathogen or viral, fungal, or parasitic pathogen as the sole cause of infection
- •12. Anticipated need for antibacterial therapy longer than 14 days (example, osteomyelitis or endocarditis); this applies to both study treatment with cefiderocol, as well as adjunctive IV antibacterial treatment for suspected coinfection with Gram-positive organisms or multidrug resistant Gram-negative organisms
- •13. Suspected or confirmed central nervous system infection (CNS), including suspected CNS infection who do not have a lumbar puncture but who are treated for potential CNS infection, evidence suggestive of CNS infection based on LP results (polymorphonuclear pleocytosis, hypoglycorrhachia, and increased protein concentration), regardless of culture results, LP with organisms on Gram stain or culture-positive cerebrospinal fluid
研究者
相似试验
进行中（未招募）
1 期
A clinical study to assess the safety and efficacy of AMG 145 on low density cholesterol in subjects with homozygous familial hypercholesterolemia or PCSK9 mutationsHomozygous Familial HypercholesterolemiaMedDRA version: 14.1Level: LLTClassification code 10057100Term: Homozygous familial hypercholesterolaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005400-15-GRAmgen Inc75
进行中（未招募）
1 期
A pharmacokinetics and safety study of cefiderocol in hospitalized pediatric patients from birth to less than 3 months of age with suspected or confirmed Gram-negative bacterial infectionsAerobic Gram-negative bacterial infectionsCTIS2023-503757-35-00Shionogi B.V.40
进行中（未招募）
1 期
Macitentan pharmacokinetics (PK) in children below 2 years of agePulmonary Arterial HypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2022-002754-74-PLACTELION Pharmacteuticals Ltd.10
进行中（未招募）
1 期
Macitentan pharmacokinetics (PK) in children below 2 years of agePulmonary Arterial HypertensionEUCTR2022-002754-74-DEACTELION Pharmacteuticals Ltd.10
招募中
不适用
A single-arm, open-label, multicenter study to assess molecular response of P1101 therapy in patients with polycythemia vera and elevated hematocritNeoplasmsKCT0006138The Catholic University of Korea, Seoul St. Mary's Hospital93